Overview: Human Epididymis Protein 4 TestIntroduction: The Human Epididymis Protein 4 Test measures HE4 to diagnose ovarian cancer, causing pelvic pain or bloating. Aligned with 2023 ASCO guidelines, it uses an immunoassay for high sensitivity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected ovarian malignancies, often used with CA-125.
Other Names: HE4 Assay, Ovarian Cancer Marker Test.
FDA Status: FDA-cleared diagnostic test, meeting immunology standards for diagnostic accuracy.
Historical Milestone: HE4 testing began in the 2000s with ovarian cancer research. Immunoassays improved in the 2010s, enhancing specificity for cancer diagnosis.
Purpose: Diagnoses ovarian cancer, guides treatment, and monitors HE4 levels in patients with pelvic pain or bloating.
Test Parameters: 1. Human Epididymis Protein 4
Pretest Condition: No fasting required. Collect serum or plasma at any time. Report symptoms like pelvic pain or bloating, and list medications.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document pelvic pain, bloating, or history of ovarian cancer. Include current medications, especially chemotherapeutics, and family history.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for cancer treatment.
Procedural Considerations: Uses an immunoassay to measure HE4 levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Hemolysis, improper storage, or non-malignant conditions (e.g., endometriosis) can affect results. Early-stage cancer may yield low levels.
Clinical Significance: Elevated HE4 levels suggest ovarian cancer, prompting further evaluation or treatment. Normal levels may require additional testing.
Specialist Consultation: Consult an oncologist or gynecologist for result interpretation and cancer management planning.
Additional Supporting Tests: CA-125, pelvic ultrasound, or CT to confirm ovarian cancer diagnosis and stage.
Test Limitations: Non-specific elevations may occur in benign conditions. Clinical correlation and additional markers are needed.
References: ASCO Ovarian Cancer Guidelines, 2023; Journal of Clinical Oncology, Moore RG, 2022.
